Investigational drug · Phase 2
AT02
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyloidosis; Systemic.
Phase 2Last checked: Nov 19, 2026Latest source record: May 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "AT02"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AT02", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyloidosis; Systemic
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "AT02" as an intervention, largest first.
- A Study of AT-02 in Subjects With Systemic Amyloidosis.Active, not recruiting
Attralus, Inc.Industry
NCT05951049 · 120 participants (planned) · Start Sep 21, 2023 · Primary completion Sep 28, 2026
Drug: AT02 · For: Amyloidosis; Systemic
Sites: Kansas City, Kansas; Cleveland, Ohio; Portland, Oregon · 4 sites in all
- Study of AT-02 in Healthy Volunteers and Subjects With Systemic AmyloidosisPivotal-lookingStatus unknown
Attralus, Inc.Industry
NCT05521022 · 100 participants (planned) · Start Sep 1, 2022 · Primary completion Mar 1, 2025
Drug: AT-02 · For: Amyloidosis; Systemic
Sites: Overland Park, Kansas; Baltimore, Maryland; Kansas City, Missouri · 11 sites in all
Dhp Korea Co., Ltd.Industry
NCT00788229 · 72 participants · Start Nov 2008 · Primary completion Aug 2009
Drug: AT01; AT02 and 2 more · For: Dry Eye Syndromes; Keratoconjunctivitis Sicca
Sites: Seoul, South Korea
- Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDSActive, not recruiting
Aqualung Therapeutics Corp.Industry
NCT05938036 · 15 participants · Start Dec 1, 2023 · Primary completion May 1, 2027
Drug: ALT-100 mAb; ALT-100 (Placebo) · For: Acute Respiratory Distress Syndrome (ARDS)
Sites: Tucson, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- Current and emerging treatment options for transthyretin amyloid cardiomyopathy.
Vergaro G, Ferrari Chen YF, Ioannou A, et al. · Heart 2026
- Pan-Amyloid Reactive Peptides p5+14 and p5R Exhibit Specific Charge-Dependent Binding to Glycosaminoglycans.
Hancock TJ, Williams AD, Foster JS, et al. · Pharmaceuticals (Basel) 2025
- The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivity.
Wall JS, Williams AD, Balachandran M, et al. · NPJ Drug Discov 2025
- New therapies to treat cardiac amyloidosis.
Nguyen O, Kamna D, Masri A · Curr Opin Cardiol 2025
- Arsenic efflux and bioremediation potential of Klebsiella oxytoca via the arsB gene.
Waqar S, Tariq A, Ullah U, et al. · PLoS One 2025
- Production of Escovopsis conidia and the potential use of this parasitic fungus as a biological control agent of leaf-cutting ant fungus gardens.
Queiroz RRS, Teodoro TBP, Carolino AT, et al. · Arch Microbiol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.